<DOC>
	<DOCNO>NCT02728180</DOCNO>
	<brief_summary>The main purpose trial determine whether Xingnaojing , intravenously administer within 24 hour symptom onset , improve 3-month outcome participant acute ischemic stroke .</brief_summary>
	<brief_title>Xingnaojing Moderate-to-severe Acute Ischemic Stroke ( XMAS )</brief_title>
	<detailed_description>Xingnaojing widely use China , lack high-quality evidence efficacy acute ischemic stroke currently . The primary hypothesis trial Xingnaojing increase proportion people alive independent three month . Xingnaojing , combine guidelines-based standard care , compare standard care alone patient acute ischemic stroke within 24 hour symptom onset . All patient National Institutes Health Stroke Scale ( NIHSS ) entry score 5-20 . Patients group treat accord guidelines-based standard care , include intravenous thrombolysis appropriate . The primary outcome determine 3 month .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Acute ischemic stroke within 24 hour symptom onset . National Institutes Health Stroke Scale score ≥ 5 ≤ 20 . Age ≥ 35 ≤ 80 year . Patient legally authorize representative sign informed consent . Planned already receive endovascular treatment . Suspected secondary stroke cause tumor , brain trauma , hematologic disease . Already dependent activity daily live present acute stroke ( define modify Rankin Scare score ≥2 ) . Other condition lead motor dysfunction ( e.g . severe osteoarthrosis , rheumatoid arthritis ) . Significant renal hepatic insufficiency ( define serum creatinine concentration , alanine aminotransferase , aspartate aminotransferase value twice great upper limit normal ) . Life expectancy 90 day less due life threaten illness ( e.g . advanced cancer ) . Other condition render outcome followup unlikely assessed.. Known pregnant breastfeeding . Currently receive investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acute Ischemic Stroke</keyword>
	<keyword>Xingnaojing injection</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Traditional Chinese Medicine</keyword>
</DOC>